PNC Financial Services Group’s Theravance Biopharma TBPH Stock Holding History

PNC Financial Services Group’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.44K	Buy	555 +47	+9%	+$778	﹤0.01%	4115
2026 Q1	$8.24K	Buy	508 +200	+65%	+$3.54K	﹤0.01%	4038
2025 Q4	$5.76K	Buy	308 +6	+2%	+$100	﹤0.01%	4174
2025 Q3	$4.41K	Sell	302 -21	-7%	-$265	﹤0.01%	4252
2025 Q2	$3.56K	Buy	323 +28	+9%	+$272	﹤0.01%	4239
2025 Q1	$2.63K	Sell	295 -145	-33%	-$1.35K	﹤0.01%	4273
2024 Q4	$4.14K	Sell	440 -446	-50%	-$4.06K	﹤0.01%	4094
2024 Q3	$7.14K	Buy	886 +391	+79%	+$3.39K	﹤0.01%	3920
2024 Q2	$4.2K	Sell	495 -592	-54%	-$5.34K	﹤0.01%	4042
2024 Q1	$9.75K	Buy	1,087 +946	+671%	+$8.77K	﹤0.01%	3758
2023 Q4	$1.58K	Sell	141 -3	-2%	-$30	﹤0.01%	4229
2023 Q3	$1.24K	Hold	144	–	–	﹤0.01%	4335
2023 Q2	$1.49K	Hold	144	–	–	﹤0.01%	4443
2023 Q1	$1.56K	Hold	144	–	–	﹤0.01%	4361
2022 Q4	$1.62K	Hold	144	–	–	﹤0.01%	4311
2022 Q3	$2K	Hold	144	–	–	﹤0.01%	4214
2022 Q2	$2K	Hold	144	–	–	﹤0.01%	4240
2022 Q1	$2K	Buy	144 +56	+64%	+$549	﹤0.01%	4230
2021 Q4	$0	Hold	88	–	–	﹤0.01%	4607
2021 Q3	$0	Hold	88	–	–	﹤0.01%	4401
2021 Q2	$2K	Hold	88	–	–	﹤0.01%	4058
2021 Q1	$2K	Buy	88 +32	+57%	+$608	﹤0.01%	3976
2020 Q4	$0	Hold	56	–	–	﹤0.01%	4065
2020 Q3	$0	Hold	56	–	–	﹤0.01%	4043
2020 Q2	$2K	Hold	56	–	–	﹤0.01%	3795
2020 Q1	$2K	Hold	56	–	–	﹤0.01%	3754
2019 Q4	$2K	Hold	56	–	–	﹤0.01%	3810
2019 Q3	$2K	Hold	56	–	–	﹤0.01%	3871
2019 Q2	$0	Hold	56	–	–	﹤0.01%	4129
2019 Q1	$2K	Hold	56	–	–	﹤0.01%	3891
2018 Q4	$2K	Hold	56	–	–	﹤0.01%	3874
2018 Q3	$2K	Sell	56 -100	-64%	-$2.73K	﹤0.01%	3967
2018 Q2	$4K	Buy	156 +100	+179%	+$2.37K	﹤0.01%	3894
2018 Q1	$2K	Buy	56 +20	+56%	+$549	﹤0.01%	4058
2017 Q4	$2K	Buy	+36	New	+$1.06K	﹤0.01%	4023
2016 Q4	–	Sell	-5,800	Closed	-$210K	–	4091
2016 Q3	$210K	Sell	5,800 -192	-3%	-$5.35K	﹤0.01%	2065
2016 Q2	$136K	Buy	5,992 +192	+3%	+$4.15K	﹤0.01%	2313
2016 Q1	$110K	Hold	5,800	–	–	﹤0.01%	2434
2015 Q4	$96K	Hold	5,800	–	–	﹤0.01%	2476
2015 Q3	$64K	Hold	5,800	–	–	﹤0.01%	2762
2015 Q2	$76K	Sell	5,800 -15	-0.3%	-$233	﹤0.01%	2797
2015 Q1	$100K	Buy	5,815 +15	+0.3%	+$275	﹤0.01%	2686
2014 Q4	$86K	Sell	5,800 -5,884	-50%	-$103K	﹤0.01%	2553
2014 Q3	$270K	Buy	11,684 +11,400	+4,014%	+$331K	﹤0.01%	1819
2014 Q2	$10K	Buy	+284	New	+$8.55K	﹤0.01%	3133

Other funds holding TBPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MCC

Money Concepts Capital Palm Beach Gardens, Florida $2.16B AUM 28.67% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PNC Financial Services Group's TBPH Position: Q2 2026 in Review

PNC Financial Services Group increased its Theravance Biopharma (TBPH) stake by 9.3% in Q2 2026, buying an estimated $778 and bringing the position to 555 shares worth $9.44K. The position accounts for ﹤0.01% of the portfolio, ranked #4115.

PNC Financial Services Group first reported a position in TBPH in Q2 2014 and has held it in 45 quarters since. The position peaked at $270K in Q3 2014. 56 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

PNC Financial Services Group held 555 shares of Theravance Biopharma worth $9.44K as of Q2 2026.
PNC Financial Services Group bought 47 Theravance Biopharma shares in Q2 2026, an estimated $778.
Theravance Biopharma made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4115 holding.
PNC Financial Services Group first reported a position in Theravance Biopharma in Q2 2014 and has held it in 45 quarters since.
PNC Financial Services Group's Theravance Biopharma position peaked at $270K in Q3 2014.
56 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.